Results 121 to 130 of about 4,565 (192)

Cost-utility and budget impact analyses of anaplastic lymphoma kinase inhibitors in Thailand. [PDF]

Sci Rep
Luksameesate P, Phatchararuangkit N, Soopairin S, Vinayanuwattikun C, Kulthanachairojana N, Taychakhoonavudh S.   +5 more
europepmc   +1 more source

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario [PDF]

, 2018
Addeo, Alfredo, Buffoni, Lucio, Novello, Silvia, Robinson, Tim, Tabbò   +4 more
core   +1 more source

Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors. [PDF]

BMC Cancer
Xu J, Zhu A, Xu Y, Zhang Y, Shen Y, Niu Y, Zhong H, Zhong R.   +7 more
europepmc   +1 more source

Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system. [PDF]

Front Neurol
Wei X, Lai Q, Zheng L.
europepmc   +1 more source

Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience. [PDF]

Cancers (Basel)
Ćeriman Krstić V, Samardžić N, Stjepanović M, Popević S, Adžić-Vukičević T, Glumac S, Stević R, Marić D, Velinović M, Jovanović M, Ilić B, Gajić M, Čolić N, Lukić K, Maračić BM, Stamenić S, Radovanović IS, Lazović JM.   +17 more
europepmc   +1 more source

Alectinib Efficacy Post-Brigatinib Against Advanced <i>ALK</i>+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study). [PDF]

Lung Cancer (Auckl)
Descourt R, Guisier F, Pérol M, Cadranel J, Doubre H, Duruisseaux M, Culine S, Mennecier B, Bylicki O, Chouaid C, Greillier L.   +10 more
europepmc   +1 more source

Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors. [PDF]

Front Pharmacol
Gu J, Zhang J, Li S, Lin Z, Huang L, Zhou Y.   +5 more
europepmc   +1 more source

Patient-derived organoid facilitating personalized medicine in non-small cell lung cancer: two case reports. [PDF]

Front Oncol
Qin L, Wang S, Li L, Qin H.
europepmc   +1 more source

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer. [PDF]

Transl Lung Cancer Res
Morise M, Tanaka I, Ishii M.
europepmc   +1 more source

High-Speed Atomic Force Microscopy Reveals Disordered Region-Mediated Structural Plasticity of Anaplastic Lymphoma Kinase Fusion Proteins Induced by Inhibitors. [PDF]

ACS Nano
Han X, Kodera N, Yilmaz N, Sakai K, Arai S, Li B, Imamura R, Voon DC, Fukuda K, Nanjo S, Flechsig H, Mano H, Matsumoto K, Yano S.   +13 more
europepmc   +1 more source